SCHEMBL4936027

SCHEMBL4936027

CCCC(Br)C(=O)c1ccc(CO)cc1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 10/20 0.56
SLC6A2 P23975 8/20 0.56
TAS1R3 Q7RTX0 2/20 0.41
TAS1R1 Q7RTX1 2/20 0.41
SLC6A4 P31645 5/20 0.40
PRKCA P17252 1/20 0.39
PRKCD Q05655 1/20 0.39
BDKRB2 P30411 1/20 0.37
EPHX2 P34913 1/20 0.36
ADRB2 P07550 1/20 0.36
ADRB1 P08588 1/20 0.36
ADRB3 P13945 1/20 0.36
PRSS1 P07477 1/20 0.36
PRSS2 P07478 1/20 0.36
PRSS3 P35030 1/20 0.36
ALDH1A1 P00352 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17644172 0.82 SLC6A2 (0.54) SLC6A3SLC6A2SLC6A4ADRB1ADRB3
SCHEMBL4935111 0.82 SLC6A3 (0.56) SLC6A3SLC6A2SLC6A4ALDH1A1KMT2A
SCHEMBL4937398 0.82 SLC6A3 (0.54) SLC6A3SLC6A2SLC6A4ALDH1A1KMT2A
SCHEMBL4936099 0.81 GSK3B (0.58) SLC6A3SLC6A2SLC6A4
SCHEMBL4936186 0.81 SLC6A3 (0.55) SLC6A3SLC6A2SLC6A4ALDH1A1
SCHEMBL2823791 0.80 SLC6A2 (0.53) SLC6A3SLC6A2PRSS1KMT2A
SCHEMBL4935875 0.80 SLC6A2 (0.53) SLC6A3SLC6A2PRSS1KMT2A
SCHEMBL12970402 0.78 SLC6A2 (0.46) SLC6A3SLC6A2EPHX2ADRB2ADRB1
SCHEMBL4932919 0.78 SLC6A2 (0.57) SLC6A3SLC6A2TAS1R3TAS1R1SLC6A4
SCHEMBL4936697 0.78 SLC6A2 (0.57) SLC6A3SLC6A2TAS1R3TAS1R1SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080234498-A1 Pyrovalerone Analogues and Therapeutic Uses Thereof PRESIDENT AND FELLOW OF HARVARD COLLEGE (US) 2008-09-25 US disclosed
EP-1670755-A4 PYROVALERONE ANALOGS AND THERAPEUTIC USES THEREOF HARVARD COLLEGE (US) 2007-02-28 EP disclosed
EP-1670755-A2 PYROVALERONE ANALOGS AND THERAPEUTIC USES THEREOF President And Fellows of Harvard College (US) 2006-06-21 EP disclosed
WO-2005034878-A2 PYROVALERONE ANALOGS AND THERAPEUTIC USES THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2005-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234498-A1 Pyrovalerone Analogues and Therapeutic Uses Thereof SLC6A2, SLC6A4, SLC6A3 SLC6A3 3/4885SLC6A2 1/4885TAS1R3 1426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.